eduKate Learning Manual: Veterinary Therapeutic Drug Monitoring | Why a “Therapeutic” Blood Level Does Not Prove the Treatment Is Right

Veterinary World · eduKate Learning Manual

Part 1 — Wait, What?

A dog can have a drug concentration inside a published therapeutic range and still have poor disease control. Another animal can sit near the edge of that range and be clinically stable.

The laboratory number is not lying. The word therapeutic is simply easier to misunderstand than it first appears.

A therapeutic range is a population-informed interpretive tool. It is not a guarantee that every individual inside the interval is effectively treated or that every individual outside it is automatically unsafe.

Part 2 — The Scientific Job

This manual owns the veterinary scientific job of interpreting measured drug concentrations in relation to sampling time, pharmacokinetics, steady state, laboratory method, efficacy, adverse effects and individual variability.

It explains why a concentration only becomes meaningful when we know what drug was measured, when the sample was taken relative to administration, whether the patient had reached a reasonably stable exposure state, what specimen and assay were used, and what the animal was actually experiencing.

It does not own prescribing, dose selection, seizure treatment, individual dose calculations, antimicrobial dosing, polypharmacy reconciliation, adverse-drug-event causality or general species-specific pharmacology. Those remain with their existing Veterinary World and specialist owners. The job here is measurement interpretation: how a concentration becomes clinical evidence without becoming an automatic instruction.

Part 3 — Quick Answer

Therapeutic drug monitoring, or TDM, measures the concentration of selected medicines in blood or serum when that measurement can improve treatment interpretation. It is most useful when drug exposure varies meaningfully between patients, clinical effects are not fully predictable from the administered dose, concentration relates to efficacy or toxicity, or the consequences of under- or over-exposure matter.

The number is only one layer. Sampling before a dose and sampling near a post-dose peak can produce different concentrations. A newly started medicine may not yet have reached steady state. Concurrent disease can alter absorption, protein binding, metabolism or elimination. Laboratory handling can alter some measurements. The result therefore belongs to a timeline and a patient.

Part 4 — Primary Entry

Imagine checking the water level in a bath while the tap is running and the drain is open.

If you measure just after turning the tap up, the level may still be rising. If you measure later, inflow and outflow may have settled into a repeating pattern. The same bath can therefore give different readings depending on when you look.

A medicine in the body behaves more complexly, but the lesson transfers. Administration adds drug. Absorption, distribution, metabolism and elimination change the amount and location over time. A concentration without a sampling time is an answer missing part of its question.

Part 5 — Secondary Deepening

After repeated administration, some medicines approach a repeating exposure pattern called steady state. This does not mean the concentration becomes flat. It means that, under reasonably stable conditions, the pattern between administrations becomes more predictable because average input and elimination have reached balance.

A trough sample is collected near the lowest concentration in a dosing interval, usually just before the next scheduled administration. A peak-oriented sample answers a different question. Neither is universally “better”; the useful timing depends on the medicine and the clinical purpose.

Phenobarbital is a useful veterinary example because serum monitoring is well established in dogs. It has a long half-life, reaches steady state over weeks and can alter its own metabolism through hepatic enzyme induction. Veterinary guidance therefore links concentration interpretation to treatment duration, timing, efficacy, tolerance and periodic reassessment rather than to one isolated number.

Part 6 — JC Deepening

The central TDM equation is conceptual rather than arithmetic:

Observed concentration = administered regimen × absorption/distribution/metabolism/elimination × sampling time × analytical method × patient state.

Every term can move. Gastrointestinal disease can change absorption. Hypoalbuminaemia can alter protein binding for some drugs. Kidney or liver dysfunction can alter clearance. Drug interactions can induce or inhibit metabolism. Growth, ageing and species differences can change pharmacokinetics. Even perfect adherence does not guarantee identical concentrations in two animals receiving the same nominal amount per kilogram.

A therapeutic range is also a statistical and clinical construct, not a biological wall. The 2015 ACVIM consensus on canine seizure management explicitly describes therapeutic ranges as population-based and recommends individual interpretation according to efficacy and tolerance. That distinction prevents a common error: treating the interval as if the laboratory had already made the clinical decision.

Part 7 — How Do We Know?

Veterinary consensus guidance for canine seizure medicines provides one of the clearest demonstrations of TDM reasoning. For phenobarbital, serial concentrations are interpreted after sufficient time for steady state and then revisited after meaningful treatment changes or at planned intervals. The same guidance explains that an individual animal can respond outside the centre of a population therapeutic interval.

The Merck Veterinary Manual likewise ties phenobarbital concentration monitoring to pharmacokinetics, chronic enzyme induction, clinical seizure control and adverse-effect monitoring. It also warns that some collection materials can falsely lower measured concentrations of phenobarbital or benzodiazepines. That is an important preanalytical bridge: a concentration can be biologically meaningful only if the specimen preserved the quantity we intended to measure.

TDM is not equally useful for every medicine. If a drug has a wide safety margin, a clear clinical endpoint and no well-established concentration–response relationship, measuring its blood concentration may add little. The scientific question is therefore not “Can we measure it?” but “Will this measurement reduce uncertainty that matters?”

Part 8 — Observation vs Inference

Observation: a dog’s phenobarbital concentration lies within a published therapeutic range but seizures remain poorly controlled. Inference: drug exposure is not obviously absent, but the result does not prove adequate treatment for this individual or identify why control is poor.

Observation: a measured concentration is unexpectedly low, and the sample was collected using a tube known to interfere with that drug measurement. Inference: preanalytical error is a plausible explanation and should be resolved before attributing the result to the animal.

Observation: two samples from the same animal differ substantially, but one was taken before the next dose and the other several hours after administration. Inference: the difference may reflect expected pharmacokinetic timing rather than unstable adherence or laboratory error.

Part 9 — Evidence Boundaries

A dose is not a concentration. A concentration is not an effect. An effect is not automatically a benefit. TDM connects these layers but does not collapse them.

A population therapeutic range is not a universal target for every species, indication or patient. Published ranges must be matched to the actual drug, species, assay and clinical context.

A concentration taken before steady state may answer a legitimate urgent question, but it should not be interpreted as if it represented a stable long-term exposure pattern.

Clinical response and toxicity remain independent evidence. If the animal is deteriorating, a reassuring laboratory concentration cannot overrule the patient.

Part 10 — Common Misconceptions

“Therapeutic range means guaranteed effective.” It is a population-informed interval, not an individual promise.
“The same dose per kilogram gives the same concentration.” Pharmacokinetic variability can be substantial.
“Any blood sample is fine.” Timing, specimen type and handling can materially affect interpretation.
“Once a stable concentration is reached it never changes.” Disease, interactions, ageing, adherence and metabolism can change exposure.
“Every medicine should have drug levels measured.” TDM is valuable only when concentration information improves a real decision.
“A good concentration makes clinical monitoring unnecessary.” Efficacy and adverse effects remain patient-level evidence.

Part 11 — Unfamiliar Transfer

Two dogs receive the same medicine at the same nominal regimen. Dog A has stable liver and kidney function. Dog B develops a disease that reduces clearance. The prescription has not changed, but the internal exposure can.

Now reverse the problem. One dog’s measured concentration remains similar across months, yet clinical control deteriorates. The stable number should not force us to assume the biological system is unchanged. Disease progression, altered sensitivity or an additional diagnosis may sit outside the concentration measurement.

The wider transfer applies to many measurements in science: a value becomes interpretable only after its position in a process is known. Time is part of the specimen.

Part 12 — Checkpoint Questions

Why is sampling time part of a drug concentration result?
What does steady state mean—and what does it not mean?
Why is a therapeutic range not an absolute biological boundary?
How can two animals on the same nominal regimen have different concentrations?
Why can specimen collection equipment matter?
When might measuring a drug concentration add little useful information?

Answer Key

1. Drug concentration changes across the dosing interval, so the timestamp determines what phase of exposure was sampled. 2. Average input and elimination have reached a repeating balance; the concentration can still fluctuate within each interval. 3. It is derived from populations and must be reconciled with individual efficacy and tolerance. 4. Absorption, distribution, metabolism, elimination, disease, interactions and adherence can differ. 5. Some materials can adsorb or otherwise alter measured drug concentration. 6. When concentration has no validated relationship to efficacy or toxicity and clinical monitoring already answers the relevant question well.

Part 13 — Edge Science

Veterinary pharmacology is moving towards model-informed precision dosing, population pharmacokinetics, Bayesian forecasting and richer longitudinal monitoring. These methods can combine a small number of measured concentrations with prior pharmacokinetic knowledge to estimate an individual patient’s exposure pattern.

The opportunity is substantial, but the evidence boundary must remain visible. A mathematical model can estimate an unmeasured parameter; it cannot turn poor sampling, wrong drug identity, uncertain administration history or an unrelated clinical deterioration into good evidence.

The best future use of TDM will therefore be neither “follow the laboratory range” nor “ignore the laboratory”. It will be a disciplined conversation between measured exposure, the animal’s response and a model that remains correctable when the patient behaves differently.

Part 14 — Veterinary World Direction Graph

Drug administration → absorption/distribution → circulating concentration → metabolism/elimination.
Repeated administration + time → approach to a repeating exposure pattern.
Clinical question → choose whether concentration measurement can reduce meaningful uncertainty.
Sample timing + specimen handling + validated assay → interpretable measured concentration.
Concentration + efficacy + adverse effects + organ function + interactions → patient-level interpretation.
Polypharmacy or adverse-event causality question → hand off to existing Veterinary World owners.
Individual prescribing or dose change → hand off to the treating veterinarian.

Part 15 — Research Sources and Further Reading

Educational Safety Boundary

This Learning Manual is educational. It does not provide medicine doses, target concentrations for an individual animal, loading instructions, tapering instructions or advice to change a prescription. Never alter or stop a veterinary medicine because of a general therapeutic range or a single laboratory result. Poor seizure control, suspected toxicity, collapse, severe sedation, jaundice, vomiting, bleeding, behavioural change or other concerning signs require prompt professional veterinary assessment.

Part 17 — Teaching Guide for Parents, Tutors and Teachers

Draw a simple concentration-versus-time curve after repeated imaginary administrations. Mark a peak, a trough and the period before steady state. Ask learners to place three blood samples on the curve and explain why the same numerical result could mean something different at each time.

Then give two fictional patients with the same concentration but different outcomes: one clinically controlled, one not. Students must explain why “inside the range” cannot finish the reasoning.

For the final exercise, deliberately introduce a specimen problem. Tell learners that a collection tube can alter the measured concentration of a particular drug. Ask them to separate patient biology, treatment history and laboratory handling into three columns. The deeper lesson is that evidence has a journey. Before a number reaches the screen, the animal, time, specimen and method have all touched it.